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Abstract
Background: One of the hallmarks of Alzheimer’s disease, and several other degenerative disorders such as
Inclusion Body Myositis, is the abnormal accumulation of amyloid precursor protein (APP) and its proteolytic
amyloid peptides. To better understand the pathological consequences of inappropriate APP expression on
developing tissues, we generated transgenic flies that express wild-type human APP in the skeletal muscles, and
then performed anatomical, electrophysiological, and behavioral analysis of the adults.
Results: We observed that neither muscle development nor animal longevity was compromised in these
transgenic animals. However, human APP expressing adults developed age-dependent defects in both climbing
and flying. We could advance or retard the onset of symptoms by rearing animals in vials with different surface
properties, suggesting that human APP expression-mediated behavioral defects are influenced by muscle activity.
Muscles from transgenic animals did not display protein aggregates or structural abnormalities at the light or
transmission electron microscopic levels. In agreement with genetic studies performed with developing
mammalian myoblasts, we observed that co-expression of the ubiquitin E3 ligase Parkin could ameliorate human
APP-induced defects.
Conclusions: These data suggest that: 1) ectopic expression of human APP in fruit flies leads to age- and activity-
dependent behavioral defects without overt changes to muscle development or structure; 2) environmental
influences can greatly alter the phenotypic consequences of human APP toxicity; and 3) genetic modifiers of APP-
induced pathology can be identified and analyzed in this model.
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Background
Amyloid precursor protein (APP) is a type I glycotrans-
membrane protein with a large extracellular domain and
a short cytoplasmic tail [reviewed in 1]. Its role in nor-
mal biological processes is poorly defined, but there is
mounting evidence that it plays both autocrine and
endocrine roles in neurite growth and enhanced mem-
ory function in mice [2,3].
APP became the subject of intense investigation when
it was identified as a risk factor for Alzheimer’s disease
(AD) [4]. Individuals with an extra copy of the APP
gene due to trisomy of chromosome 21 (Down Syn-
drome) also display early onset AD [5]. One point muta-
tion in APP, referred to as the Swedish mutation, results
in an early onset familial AD [6].
APP can be subjected to combinatorial cleavage by
three different intramembrane secretases (a, b, and g)t o
create a number of smaller peptides [7]. Cleavage by a-
secretase, known as a non-amyloidogenic pathway, is
responsible for a default secretory pathway and predo-
minates in all non-neuronal cells. Cleavage by BACE (b-
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in most cell types, except for neurons. Like a-secretase
cleavage of APP, the BACE-mediated fragment of APP
undergoes further proteolysis by a g-secretase complex
to generate small peptides that typically range between
40-44 amino acids, although 46 amino acid fragments
can be found in skeletal muscles. APP cleavage products
are enriched in the brains of some AD patients [8], and
exposure to the Ab42 fragment is highly neurotoxic both
in vitro and in in vivo animal models [9,10].
In addition to its well-documented roles in neurode-
generation, APP and its cleaved products have been also
implicated in other diseases, most notably sporadic
inclusion body myositis (s-IBM) [11], the most common
skeletal muscle disorder of the elderly [12,13]. It has
been reported that muscle biopsies from individuals
with s-IBM contain Congo Red inclusions that are
immunopositive for both APP [11] and Ab42 [14]. How-
ever, this is not a universal observation [15], and proteo-
mic analysis of IBM samples failed to reveal any APP
proteolytic products [16]. In fact, a fundamental role for
APP in the pathogenesis of s-IBM has been questioned
recently [12,17,18].
While the role of APP in s-IBM awaits further analysis
of clinical samples, it has been demonstrated that ecto-
pic expression of either APP (either wild-type or Swed-
ish mutant) or Ab42 is sufficient to induce cell death in
skeletal muscle either in vitro [19,20] or in vivo [21-23].
The biology of muscle makes it a much more tractable
tissue to study than the central nervous system. Thus,
studies designed to examine the effects of APP on mus-
cle development and physiology may provide new
insights into the general mechanisms that mediate APP
induced pathogenesis.
To help define the mechanisms that could mediate
APP toxicity in muscle, and to develop a genetic model
for testing genetic and environmental interventions that
might reduce APP-induced pathogenesis, we generated
transgenic flies that express human APP in the skeletal
muscles. We found that both genetic and environmental
factors can interact to enhance or reduce APP-induced
behavioral defects. These data suggest that the trans-
g e n i cf l ym a yr e p r e s e n tau s e f u lt o o lf o rd e f i n i n gt h e
molecular mechanisms that mediate APP-induced mus-
cle pathology and for identifying genetic and chemical
modulators.
Results and Discussion
Muscle specific expression of human amyloid precursor
protein (hAPP) induces an age-dependent reduction in
climbing and flying activity
In order to study the role of human APP (hAPP) on the
development and function of skeletal muscles, we took
advantage of a transgenic fly line that expresses hAPP
under the control of the Upstream Activating Sequence
(UAS) [24]. These flies were crossed to a line that
expresses the Gal4 transcription factor under the control
of the muscle transcription factor Dmef [25], which
expresses in all skeletal muscles and a few circadian
neurons within the brain [26].
We employed several controls in each of these studies,
including nontransgenic w
1118 flies and transgenic flies
expressing bacterial b-galactosidase (LacZ) under the
control of Dmef-Gal4. The expression of LacZ both vali-
dated the anticipated expression of hAPP in muscles
(data not shown) and controlled any effects caused by
the competition of Gal4 promoter for general transcrip-
tional machinery within the cells. Ectopic hAPP expres-
sing flies (■) eclosed in normal numbers and displayed
comparable longevity to the control lines (▲) suggesting
that ectopic hAPP (■) was non-toxic (Figure 1B).
To assess the effects of ectopic hAPP on behavior,
flies were tested for their ability to climb (Figure 1A).
Both nontransgenic (w
1118 ●) and LacZ-expressing (■)
flies displayed comparable levels of climbing activity
during the one-month testing period. Transgenic flies
expressing hAPP exhibited wild-type levels of climbing
activity during the first two weeks of adulthood, but it
declined during the subsequent weeks (Figure 1C) so
that by the end of the fourth week, only about 20% of
the transgenic flies could climb. In contrast, 75% of 1-
month old wild-type w
1118 control animals could climb.
The climbing defect observed in transgenic flies was not
due to a loss in their negative-geotropism, but rather, an
apparent loss of strength that caused them to fall from
the test cylinder before they could reach the test mark.
To evaluate flying behavior, animals were dropped
into an oil-coated 500 ml graduated cylinder and then
scored for their ability to remain near the top. Approxi-
mately 55% of the hAPP-expressing flies (dark gray) fell
to the bottom 200 ml of the cylinder (poor fliers), while
only about 12% of the controls (light gray) fell that dis-
tance (Figure 1D). Conversely, about 70% of the controls
(light gray) remained within the top 200 ml (normal
fliers), while only 20% of the transgenic flies (dark gray)
were in this category. Taken together, the climbing and
flying assays suggest that ectopic expression of hAPP
results in an age-dependent defect in motor ability.
Electrophysiological analysis of the neuromuscular
junction
Defects in motor function could reflect aberrations
within the central nervous system, at the neuromuscular
synapse, or within the muscle itself. To narrow our
focus, we performed electrophysiological analyses of
control and hAPP-expressing adult Drosophila. Intracel-
lular glass recording microelectrodes were placed in the
thoracic dorsal longitudinal flight muscle (DLFM) and
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week old adults, and the motor neurons were stimulated
via the giant fibers using tungsten electrodes placed in
the brain or directly in the thoracic ganglion. Both w
1118
control and hAPP-expressing animals displayed normal
DFLM muscle responses comprised of an evoked junc-
tion potential and a muscle action potential when
repeatedly stimulated at 100Hz (Figure 2). There was no
significant difference in amplitude size between animals
recorded at 1 week versus animals recorded after 3
weeks (Student T-test, P < 0.05, Table 1). This suggests
that motorneuron activation reliably results in muscle
action potentials that should be sufficient to trigger a
behavioral outcome mediated by muscle contraction.
Consequently, the decay of climbing behavior in 3 week
old hAPP expressing flies is not the result of a defect in
motorneuron function and thus we focused on potential
hAPP effects on the muscle.
Anatomical analysis of muscles
To evaluate the effects of hAPP on muscle development
and function, we performed both light and electron
microscopy on the indirect flight muscles of control and
hAPP-expressing flies. In Figure 3 we examined coronal
(3 week old animals) and sagittal (4 week old animals)
sections of the thorax to examine both the flight and leg
muscles. At the light level, hematoxylin and eosin stain-
ing revealed well-developed muscles in both control (3A
and 3C) and transgenic animals (3B and 3D), consistent
with their ability to eclose, walk, climb, and fly as adults
(Figure 1). Fiber number and diameter were comparable
Figure 1 hAPP-expressing flies display age-dependent defects
in climbing and flying. A. Climbing assays with wild type and
LacZ expressing flies were performed every week. N = 136 and 85
for w
1118 and LacZ expressing flies respectively. Mean +/- SEM. B. In
order to measure the survival rates of flies, the numbers of w
1118
and hAPP expressing transgenic flies were counted every week.
Initially, 174 wild type and 166 transgenic flies were cultured. Mean
+/- SEM. C. Climbing assays with w
1118 and hAPP expressing
transgenic flies in glass vials were conducted every week. N = 174
and 166 for wild-type and transgenic animals respectively. Mean +/-
SEM. D. Flight assays with w
1118 (light gray) and hAPP expressing
flies (dark gray) were performed after five-week incubation in glass
vials. Flies between 0-200 ml represent “poor fliers”, while animals at
300-500 ml are designated as “good fliers”. N = 131 and 90 for wild-
type and transgenic animals respectively. Mean +/- SEM.
Figure 2 Electrophysiological analysis of wild-type and hAPP-
expressing flight muscles. Sample traces of intracellular recordings
of muscle responses from the DLFM following electrical stimulation
of 1 week (A) and 3 week (B) old wild-type w
1118 flies and 1 week
(C) and 3 week (D) old Dmef-hAPP flies. No obvious differences
were detected among the test groups independent of age or
genotype.
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the hypothesis that ectopic expression of hAPP does not
negatively impact myogenesis.
We also performed transmission electron microscopy
on the DLFM from 3-week old wild-type animals, which
revealed well-developed Z-lines, M-lines, contractile
apparatus and mitochondria (Figure 4A). Neither the
muscle fibers themselves nor the internal membrane
systems were swollen or disrupted. Anatomically, the
DLFM of 3-week old transgenic animals were also
grossly normal, and displayed well-defined sarcomeres
(Figure 4B). As in the control muscles, dense rows of
mitochondria were sandwiched between the bundles of
contractile elements perpendicular to the Z bands. At
the subcellular level, the organization of the TTM mus-
cles differs from that of the DLFM both in terms of sar-
comeric structure and the abundance of internal
membrane systems of the T-tubule and sarcoplasmic
reticulum (SR) (Figure 4C and 4D). At the electron
microscopic level, 3 week old wild-type and hAPP trans-
genic TTM muscles were grossly indistinguishable (Fig-
ure 4C and 4D).
Environmental control of muscle pathogenesis in hAPP-
expressing flies
We performed many replicates of the climbing assay
and consistently observed comparable age-dependent
defects in transgenic animals. At one point in the study
however, we switched from glass to polypropylene plas-
tic vials for rearing the adults. While longevity was
unchanged under these different rearing conditions
(data not shown), the severity of the hAPP-induced
climbing defect of flies cultured in the plastic vials was
significantly reduced over the course of one month (Fig-
ure 5A). In order to verify that the rearing container
impacted climbing behavior, cohorts of wild-type and
hAPP-expressing animals were separated into glass or
plastic vials and then subjected to the climbing assay.
Wild-type animals displayed statistically improved
Table 1 Amplitude sizes of recordings from the DLFM
and the TTM
DLFM TTM
Genotype N mV/Stdv/SEM mV/Stdv/SEM
1 week w
1118 22 52.3/11.5/2.5 25.8/8.8/1.8
2 week w
1118 22 53.3/18.0/3.8 23.2/7.7/1.7
1 week Dmef/hAPP 18 46.0/15.7/3.7 26.6/7.6/1.8
3 week Dmef/hAPP 22 45.0/12.4/2.6 23.2/6.8/2.0
Intracellular recordings were performed on the DLFM and TTM muscles
following electrical stimulation as described in the Materials and Methods.
Data are provided for both wild type w
1118 and Dmef/hAPP flies at both 1
week and 3 weeks. Data is in mV and presented as the mean/standard
deviation/standard error of the mean. N = number of flies tested for each
condition. No significant differences between 1 week and 3 week old flies we
observed (Student T-test, P < 0.05)
Figure 3 Light microscopy of wild-type and hAPP-expressing
flight muscles. Age-matched transverse sections from three week
old w
1118 (A) and hAPP (B) expressing flies and age-matched sagittal
sections from four week old w
1118 (C) and hAPP (D) were
conducted. Asterisks = dorsal longitudinal muscles, arrow =
tergotrochanteral muscle. Scale bar = 0.1 mm.
Figure 4 Transmission electron microscopy of wild-type and
hAPP-expressing flight muscle. Dorsal longitudinal flight muscles
(DLFM) from control (w
1118, A) and hAPP (B) transgenic flies at three
weeks of age. TTM muscles from control (w
1118, C) and hAPP (D)
transgenic animals at three weeks of age. Asterisks = mitochondria;
Arrowheads = Z bands; Arrows = sarcoplasmic reticulum. Scale bar
=1μm. Note that variations in the plane of section contribute to
apparent changes in the sizes of some ultrastructural components.
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(▲) (85% vs: 56% at week four; p < 0.05 ) (Figure 5A). A
much more dramatic effect was observed for the hAPP-
expressing animals. At 4 weeks 65% of plastic reared
animals (●) could climb versus 25% for glass-reared ani-
mals (■)( p<0 . 0 5 ) .T h eb e n e f i t so fp l a s t i cv e r s u sg l a s s
vials were restricted to the leg muscles and did not
extend to the flight muscles (Figure 5B), since we did
not observe any differences in flying activity between
these two populations. These data suggest that only
muscles that are actively challenged are the ones
affected by the type of rearing substrate.
One possible mechanism for the differential effects of
the vial composition on the development of muscle
weakness is that the smoothness of glass relative to plas-
tic requires more muscle strength to climb. To test this
hypothesis, we siliconized plastic vials to make their sur-
faces smoother, and then tested new groups of control
and transgenic animals. Survival was comparable in all
three types of vials (data not shown). Wild type control
flies climbed equally well in all three types of vials until
week 3. After that, there was a small but statistically sig-
nificant decline in climbing ability for flies reared in
glass vials (▲) relative to coated (■) and uncoated plastic
vials (●) (Figure 5C). However, the effects of vial type
were much more dramatic in the hAPP transgenic flies
(Figure 5D). Transgenic flies reared in siliconized plastic
vials (■) displayed a rapid loss of climbing activity
beginning even after the first week relative to those
reared in glass (▲) or uncoated plastic vials (●). Between
three and four weeks, there was a dramatic decline in
climbing for hAPP transgenic flies reared in glass vials.
These data suggest that the environmental factors (vial
material) can have a significant impact on APP-induced
pathogenesis.
Coexpression of human Parkin rescues a hAPP-mediated
climbing defect
Mutations in the ubiquitin E3 ligase Parkin is the pri-
mary cause of Autosomal Recessive Juvenile Parkinson-
ism [27]. Loss of Parkin function endangers some cells,
most notably midbrain dopaminergic neurons. However,
in vitro studies with muscle cells have demonstrated
that expression of ectopic Parkin can protect muscle
from the toxic effects of accumulation of amyloid pep-
tides [28]. To determine if this protein could also pro-
tect skeletal muscles in vivo from hAPP-induced
damage, we generated transgenic flies that express
h u m a nP a r k i na n d / o rh A P Pi nt h em u s c l e s ,a n dt h e n
monitored the ability of the adults to climb (Figure 6).
Flies expressing hAPP (▲) demonstrated a significant
decline in climbing ability beginning in the third week.
C o - e x p r e s s i o no fP a r k i n( ♦) rescued this defect and
allowed the flies to climb at wild type levels (Figure 6).
Figure 5 Effect of vial type on climbing behavior in wild-type
and hAPP transgenic flies. A. The climbing ability of wild type and
hAPP expressing flies reared in glass or plastic vials was determined.
Percentage represents the portion of flies displaying normal
behavior. N = 161 and 171 for wild type in plastic and glass vials,
171 and 173 for transgenic flies in plastic and glass vials,
respectively. Mean +/- SEM. Climbing was statistically different by 4
weeks (p < 0.05). The error bars for the transgenic flies reared in
glass vials were are not easily observed due to their small size. B.
Flying assay was performed with 5 week old wild type flies cultured
in glass (black) or plastic (white) vials and for hAPP expressing flies
in glass (dark gray) or plastic vials (light gray). N = 199 and 126 for
the wild-type animals reared in plastic and glass vials, and N = 126
and 128 for transgenic flies in plastic and glass vials, respectively.
Mean +/- SEM. C. Climbing assays were performed with wild type
flies cultured in glass, uncoated or siliconized plastic vials. In this set
of experiments the flies reared in glass vials displayed a slightly
better performance relative to the animals represented in Figure 5A.
N = 117, 121, and118, respectively. Mean +/- SEM. Climbing was
statistically different by 4 weeks (p < 0.05) D. Climbing assays were
performed with hAPP expressing flies reared in glass, uncoated and
siliconized plastic vials. N = 124, 118, and 141, respectively. Mean
+/- SEM.
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its possible role in human diseases, most notably Alzhei-
mer’s disease. Numerous studies have demonstrated that
ectopic expression of APP, or its proteolytic products,
most notably Ab42, can trigger synapse loss and neuron
death in both in vitro and in vivo models [9,10]. In fly,
ectopic expression of Ab42 or Ab40 results in age-depen-
dent neuron loss [29]. Interestingly, males were more
severely impacted than females, although this may
reflect differences in driver expression rather than differ-
ential gender sensitivity.
These same proteins have been proposed to accumu-
late within aggregates in patients with other diseases as
well, such as inclusion body myositis [30], although this
observation has been controversial [17,18]. Nevertheless,
experimental studies have demonstrated that ectopic
expression of either APP or Ab42 is sufficient to induce
muscle cell death both in vitro [19,20] and in transgenic
mouse models [22,23,31]. In the nematode Caenorhab-
ditis elegans, expression of Ab42 results in protein aggre-
gations within body wall muscles that result in paralysis
and reduced longevity [32-34].
The transgenic fly model described in the present
study complements and extends some of the data
obtained with mouse and worm models, as well as some
of the features of s-IBM. In s-IBM patients and animal
models designed to simulate the disorder, individuals
produce muscles that appear to be morphologically and
physiologically normal, but develop progressive age-
dependent muscle weakness in mid-to-late adulthood
[12,22,32] (Figure 1C and 1D). This loss of muscle
strength is not accompanied by detectable changes in
neuromuscular synapse activity, suggesting that the
defects arise within the muscles themselves. Indeed, we
did not observe any changes in following frequency or
spike amplitude in the muscles of our hAPP-expressing
animals (Figure 2). These data would argue against a
negative influence of hAPP expression in the small sub-
set of circadian neurons in the brain that also express
MEF2 [26]
The fly model described in this study does differ from
both s-IBM and other hAPP transgenic mouse and
worm models in that they did not produce protein
aggregates within the sarcoplasm that can be detected
with either Congo Red staining (data not shown) or
ultrastructural analysis (Figure 4). It is possible that the
level of hAPP expression was below the threshold
required for macro-aggregation, or alternatively, that
flies have intracellular mechanisms that limit aggregate
formation. It has been noted that flies do not make
inclusion bodies in the skeletal muscles with other
aggregation prone proteins, like the polyglutamine-rich
Huntington protein [35]. Nevertheless, the present fly
model may provide insight into the molecular mechan-
isms that mediate hAPP induced pathology.
Several mechanisms have been proposed for the toxic
effects of APP on skeletal muscle function including:
defective regulation of ryanodine receptor-dependent
sarcoplasmic Ca
2+ release [36], CD8+ cytotoxic T cell
invasion [37], an autophagic mechanism [38], and myos-
tatin activity [39].
The observation that ectopic expression of the ubiquitin
E3 ligase Parkin can rescue the hAPP-associated defects in
climbing in our transgenic model agrees well with in vitro
results from other groups [16,27,40,41]. At least two possi-
ble Parkin associated mechanisms can ameliorate ectopic
APP-induced behavioral defects. In mammalian muscle,
Parkin prevents hAPP-induced muscle degeneration by
inhibiting accumulation of toxic Abs and also protects
cells from mitochondrial-specific toxins like rotenone and
carbonyl cyanide 3-chlorophenylhydrazone, but not from
other toxins like calcium ionophore A23187 or H2O2 [28].
Loss of function mutations in the parkin gene result in
age-dependent defects in flight muscle maintenance in fly
and are also associated with mitochondrial defects [42].
Interestingly, these defects can be prevented by increased
mitochondrial fission [43]. Taken together, these data sup-
port the hypothesis that Parkin may reduce mitochondrial
oxidative stress or maintain respiratory functions to help
preserve mitochondrial integrity.
We have demonstrated that environmental factors,
such as rearing surface (glass versus plastic), have a dra-
matic effect on the timing and severity of hAPP-induced
pathogenesis, suggesting a possible interplay between
environmental and genetic factors. To our knowledge,
this is the first report of any behavioral activities that
can be tied to the material used for rearing flies. The
simple manipulation of changing the rearing vessel may
represent a valuable tool for genetic screens in fly
designed to identify work-associated genes in fly muscle.
Figure 6 Ectopic Parkin rescues hAPP-induced climbing defects
in transgenic flies. Climbing assays with transgenic flies expressing
hAPP alone, hParkin alone, and hAPP plus hParkin in glass vials were
conducted each week. N = 54 for all genotypes. Mean +/- SEM.
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progression of myopathies in human [44,45]. Interest-
ingly, Arnardottir et al. [44] have suggested that moder-
ate exercise may retard the symptoms of s-IBM. Rearing
flies in plastic vials greatly reduced the timing and
severity of symptoms relative to rearing in glass (Figure
5A). Since the only difference between animals reared in
glass versus plastic was the nature of the vessel, we
speculated that surface properties accounted for the
observed effects. Glass vials have a smoother surface
than plastic and therefore it is presumably harder for
the fly to climb. This extra work would increase the
mechanical stress on the muscle fibers and might con-
tribute to damage or generation of reactive oxygen spe-
cies (ROS) by mitochondria. We tried to test this
hypothesis directly by setting up devices that would
force the animal to walk more, such as placing the vials
on a slowly moving rocking table. Unfortunately, these
efforts to voluntarily increase motor activity did not
appear to alter animal behavior, so instead we changed
the surface properties of the plastic vials by siliconizing
them. This subtle manipulation had a profound effect
o nt h et i m ec o u r s ea n ds e v e r i t yo ft h eh A P P - i n d u c e d
abnormal activities. This effect was specific to the mus-
cles that were forced to work, since this treatment did
not alter flying behavior.
Conclusions
In this study, we generate a transgenic Drosophila model
that targets the expression of hAPP to the skeletal mus-
cles in order to understand its effect on muscle develop-
ment and degeneration in the adult. Ectopic expression
of hAPP causes age- and activity-dependent muscle
weakness without concomitant structural damage that
can be discerned at either the light or electron micro-
scopic levels. The effects of ectopic hAPP can be ame-
liorated by hParkin expression. Taken together, these
data suggest that in Drosophila, hAPP-induced muscle
deficits are mediated by not only genetic, but also envir-
onmental factors, and that muscle work/stress may con-
tribute to pathogenesis. This animal model is useful to
identify additional genetic and environmental modula-
tors and understand underlying mechanisms.
Methods
Generation of transgenic UAS-human Parkin Drosophila
lines
In order to generate UAS-human Parkin, pRK5-myc-
Parkin generously provided by Dr. Dawson [46] and a
pUAST vector were digested with EcoRIa n dNotI
restriction enzymes (Promega) and ligated at 16°C over-
night with T4 ligase (Promega). The construct, pUAST-
myc-human Parkin was sent to the Transgenic Droso-
phila Fly Core (Charlestown, MA) for embryonic
injections. Transgenic lines were selected and cultured
at room temperature.
Drosophila
Transgenic flies expressing human APP under the con-
trol of the Gal4 upstream activating sequence (UAS)
were provided by Dr. Kalpana White [24]. A Dmef-
GAL4 line driving the expression Gal4 in mesodermal
precursors [25] was provided by Dr. Leo Pallanck. Pro-
genies from these crosses were maintained at 25°C with
12 hour-light/dark cycle. Both males and females were
used in each experiment.
Climbing Assay and flight assay
Flies were divided into 5-7 groups of 25 flies each and
reared in standard glass or plastic vials (Genesee Scienti-
fic) as noted. In some experiments plastic vials were sili-
conized with glass cleaner (Rain-X). The vials were
exchanged every two to three days and animals were
scored weekly in the climbing assay. Briefly, after a 1
minute acclimation, the percentage of flies that could
climb past the 30ml mark in a 50ml cylinder within 30
seconds was scored as successful. Trials were performed
3 times/vial. After five weeks, the flies were subjected to
the flying test. The animals were dropped into a 500ml
graduate cylinder coated with mineral oil. The number
of immobilized flies was determined for each 100 ml
section of the cylinder.
Statistical Analysis
Statistical significance was determined using Student’sT
test and one-way-analysis of variances (ANOVA) using
GraphPad Prism software (GraphPad Software, La Jolla,
CA). Data were considered statistically significant when
their p values were 0.05 or less.
Electrophysiology
Standard methods were used to get intracellular record-
ings from the dorsal longitudinal flight muscle (DLFM)
and the tergotrochanteral muscle (TTM) [47]. Flies were
anesthetized and waxed, ventral side down, onto a small
podium in a Petri dish. The motorneurons were either
indirectly stimulated via the Giant Fiber (GF) in the brain
or directly with thoracic stimulation using two etched
tungsten electrodes and by providing pulses of 40-60V for
0.03ms using a Grass S44 stimulator (Grass Instruments).
A tungsten electrode placed in the abdominal cavity
served as a ground. Glass electrodes pulled to a resistance
of 40-60MW were filled with saline and were driven
through the cuticle into the DLFM and TTM muscle
fibers. Signals were amplified, digitized and analyzed with
pClamp 10 software to monitor amplitude size and the
ability of the muscle membrane to follow multiple stimuli
at 100HZ (Getting Instruments and Molecular Devices).
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Flies were collected at different ages, the heads and
abdomens removed, and the carcass immersed in 4%
paraformaldehyde overnight at 4°C. They were then
dehydrated, embedded in paraffin and sectioned at 10
μm followed by staining with hematoxylin and eosin for
light microscopy. For transmission electron microscopy,
flies were prepared as previously described [48,49]. A fly
was placed thorax facing upward and fully covered in a
droplet of Optimal Cutting Temperature (OCT) com-
pound on a glass microscope slide. The fly was snap fro-
zen in liquid nitrogen (-196°C) and then gently fractured
with a liquid nitrogen-chilled razor blade struck with a
hammer to longitudinally bisect the flies. Care was
taken to ensure that the droplet of tissue was completely
submerged in liquid nitrogen throughout the fracturing
process, so that at no time was any sample exposed to
air and that the razor blade contacted the OCT com-
pound, not the thorax itself. The split pieces were
immediately transferred to a container of primary fixa-
tive made of 2.5% glutaraldehyde in 0.1 M phosphate
buffer at pH 7.4, and allowed to thaw and fix overnight
at 4°C. The fixative was changed several times to ensure
its concentration was not altered by the thawing OCT.
After rinsing in 0.1 M NaPO4 buffer at pH 7.4, the tis-
sue was post-fixed in 2% osmium tetroxide in 0.1 M
NaPO4 buffer at pH 7.4 for one hour. The sample was
then rinsed in distilled water and stained with 1% uranyl
acetate for 30 minutes. It was then rinsed in water and
dehydrated through an ethanol series from 30% to
100%. The sample was then infiltrated with Spurr’s extra
low viscosity resin, and after embedding, mounted frac-
ture-surface up and thin-sectioned with a diamond knife
for TEM analysis. Multiple sections from at least eight
different flies of each genotype and age were examined
for each experiment.
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